Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)

Next Previous
Search
Trial Profile

A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Letetresgene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Adaptimmune; GlaxoSmithKline; GSK

    • Most Recent Events

    • 25 Jan 2021 Status changed from active, no longer recruiting to completed.
    • 24 Jul 2020 Planned End Date changed from 20 Aug 2020 to 30 Dec 2021.
    • 09 Mar 2020 Planned primary completion date changed from 30 Jun 2020 to 20 Aug 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top